Patient Management Protocols for Diabetic Retinopathy: Centro Hospitalar Universitário de Santo António
DOI:
https://doi.org/10.48560/rspo.31122Keywords:
Diabetes Mellitus, Diabetic Retinopathy, Intravitreal Injections, Macular EdemaAbstract
INTRODUCTION: Managing patients with diabetic retinopathy presents a growing challenge in hospitals. Being the leading cause of blindness in working-age individuals, it is essential to identify diabetic patients at risk of developing ocular complications and prevent them through available treatments. In addition, it is necessary to adapt to a large population with limited hospital resources through patient stratification by risk and harmonization of their follow-up and treatment.
METHODS: Creation of 4 action protocols for diabetic patients followed in ocular diabetes consultation at the Ophthalmology service of CHUdSA. Based on a bibliographic review to integrate the best scientific evidence to date and coordinate it with the availability of integration of these same follow-up/complementary exams/treatments in the Ophthalmology service of CHUdSA. All protocols were designed by the ocular diabetes section and were submitted for validation by the entire Ophthalmology service of CHUdSA. These protocols are general indications that do not exclude a personalized approach to each patient.
RESULTS: We present the 4 protocols designed and integrated into clinical practice at CHUdSA: - Approach to the diabetic patient in the first consultation. - Red flag diabetic retinopathy, - Treatment with intravitreal anti-VEGF, - Treatment with intravitreal corticosteroids.
CONCLUSION: Diabetic retinopathy is a significant cause of vision loss and hospital resource consumption. We consider it relevant to implement general forms of action for these patients to allow homogenization of care and adaptation to the practical needs of our service. We ensure that the designed protocols do not overlap with individualized and personalized treatment for each patient.
Downloads
References
Diep TM, Tsui I. Risk factors associated with diabetic macular edema. Diabetes Res Clin Pract. 2013;100:298-305. doi: 10.1016/j.diabetes.2013.01.011.
Standl E, Khunti K, Hansen TB, Schnell O. The global epidemics of diabetes in the 21st century: Current situation and perspectives. Eur J Prev Cardiol.2019;26: 7-14. doi: 10.1177/2047487319881021.
Solomon SD, Chew E, Duh El, Sobrin L, Sun JK, VanderBeek BL, et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40:412-18. doi: 10.2337/dc16-2641.
Xie J, Ikram MK, Cotch MF, Klein B, Varma R, Shaw JE, et al. Association of diabetic macular edema and proliferative diabetic retinopathy with cardiovascular disease: a systematic review and meta-analysis. JAMA Ophthalmol. 2017;135:586-93. doi: 10.1001/jamaophthalmol.2017.0988.
Abreu AC, Lages V, Batista P, Ribeiro A, Menéres P, Pessoa B. First 5 years of Implementation of Diabetic Screening Program in Centro Hospitalar do Porto. Rev Bras Oftalmol. 2017;76:295-9.
Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237:185-222. doi: 10.1159/000458539.
Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91:1464-74. doi: 10.1016/s0161-6420(84)34102-1.
Maglah SF, Bardisi W, Al Attah M, Khorsheed MM. The prevalence and risk factors of diabetic retinopathy in selected primary care centers during the 3-year screening intervals. J Family Med Prim Care. 2018;7:975-81. doi: 10.4103/jfmpc.jfmpc_85_18.
Martinho AC, Marques IP, Messias AL, Santos T, Madeira MH, Sousa DC, et al. Ocular and Systemic Risk Markers for Development of Macular Edema and Proliferative Retinopathy in Type 2 Diabetes: A 5-Year Longitudinal Study. Diabetes Care. 2021;44:e12-4. doi: 10.2337/dc20-1125.
Nathan DM; DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37:9-16. doi: 10.2337/dc13-2112.
Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011;154:554-9. doi: 10.7326/0003-4819-154-8-201104190-00007.
Cusick M, Chew EY, Chan CC, Kruth HS, Murphy RP, Ferris FL 3rd. Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. Ophthalmology. 2003;110:2126-33. doi: 10.1016/j.ophtha.2003.01.001.
Das R, Kerr R, Chakravarthy U, Hogg RE. Dyslipidemia and Diabetic Macular Edema: A Systematic Review and Meta-Analysis. Ophthalmology. 2015;122:1820-7. doi: 10.1016/j.ophtha.2015.05.011.
Wong TY, Sun J, Kawasaki R, Ruamviboonsuk P, Gupta N, Lansingh VC, et al. Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings. Ophthalmology. 2018;125:1608-22. doi:10.1016/j.ophtha.2018.04.007.
Panozzo G, Cicinelli MV, Augustin AJ, Battaglia Parodi M, Cunha-Vaz J, Guarnaccia G, et al. An optical coherence tomography-based grading of diabetic maculopathy proposed by an international expert panel: The European School for Advanced Studies in Ophthalmology classification. Eur J Ophthalmol. 2020;30:8-18. doi:10.1177/1120672119880394.
Chalam KV, Bressler SB, Edwards AR, Berger BB, Bressler NM, et al; Diabetic Retinopathy Clinical Research Network. Retinal thickness in people with diabetes and minimal or no diabetic retinopathy. Heidelberg Spectralis optical coherence tomography. Invest Ophthalmol Vis Sci. 2012;53:8154-61. doi:10.1167/iovs.12-10290.
Grover S, Murthy RK, Brar VS, Chalam KV. Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis). Am J Ophthalmol. 2009;148:266-71. doi:10.1016/j.ajo.2009.03.006.
Brown DM, Emanuelli A, Bandello F, Barranco JJE, Figueira J, Souied E, et al. KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. Am J Ophthalmol. 2022;238:157-172. doi:10.1016/j.ajo.2022.01.004.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, et al; YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular edema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399:741-55. doi:10.1016/S0140-6736(22)00018-6.
Hutton D, Newman-Casey PA, Tavag M, Zacks D, Stein J. Switching to less expensive blindness drug could save medicare part B $1b billion over a ten-year period. Health Aff. 2014;33:931-9. doi:10.1377/hlthaff.2013.0832.
Gonzalez VH, Campbell J, Holekamp NM, Kiss S, Loewenstein A, Augustin AJ, et al. Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol. 2016;172:72-79. doi:10.1016/j.ajo.2016.09.012.
Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NMet al; Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016 ;123:1351-9. doi:10.1016/j.ophtha.2016.02.022.
Dugel PU, Campbell JH, Kiss S, Loewenstein A, Shih V, Xu X, et al. Association between early anatomic response to anti-vascular endothelial growth factor therapy and long-term outcome in diabetic macular edema: an independent analysis of protocol i study data. Retina. 2019;39:88-97. doi:10.1097/IAE.0000000000002110.
Amoaku WM, Ghanchi F, Bailey C, Banerjee S, Banerjee S, Downey L, et al. Diabetic retinopathy and diabetic macular edema pathways and management: UK Consensus Working Group. Eye. 2020;34:1-51. doi:10.1038/s41433-020-0961-6.
Merante D, Menchini F, Truitt KE, Bandello FM. Diabetic macular edema: correlations with available diabetes therapies--evidence across a qualitative review of published literature from MEDLINE and EMBASE. Drug Saf. 2010;33:643-52. doi:10.2165/11538340-000000000-00000.
Downey L, Acharya N, Devonport H, Gale R, Habib M, Manjunath V, et al. Treatment choices for diabetic macular edema: a guideline for when to consider an intravitreal corticosteroid, including adaptations for the COVID-19 era. BMJ Open Ophthalmol. 2021;6:e000696. doi:10.1136/bmjophth-2020-000696.
Pessoa B, Coelho J, Correia N, Ferreira N, Beirão M, Meireles A. Fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN
∗
∗
) in vitrectomized versus nonvitrectomized eyes for the treatment of chronic diabetic macular edema. Ophthalmic Res. 2018;59:68-75. doi:10.1159/000484091.
Pessoa B, Castro C, Ferreira A, Leite J, Heitor J, Meneres P, et al. Changes in ganglion cell layer thickness after treatment with the 0.2 μg/day fluocinolone acetonide implant in vitrectomized and nonvitrectomized eyes with diabetic macular edema. Ophthalmic Res. 2022;65:310-20. doi:10.1159/000520411.
Bandello F, Toni D, Porta M, Varano M. Diabetic retinopathy, diabetic macular edema, and cardiovascular risk: the importance of a long-term perspective and a multidisciplinary approach to optimal intravitreal therapy. Acta Diabetol. 2020;57:513-26. doi:10.1007/s00592-019-01453-z.
Chawan-Saad J, Wu M, Wu A, Wu L. Corticosteroids for Diabetic Macular Edema. Taiwan J Ophthalmol. 2019;9:233-42. doi:10.4103/tjo.tjo_68_19.
Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113:1533-8. doi:10.1016/j.ophtha.2006.02.065.
Figueira J, Henriques J, Carneiro A, Marques-Neves C, Flores R, Castro-Sousa JP, et al. Guidelines for the management of center-involving diabetic macular edema: treatment options and patient monitorization. Clin Ophthalmol. 2021;30:15:3221-3230. doi:10.2147/OPTH.S318026.
Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, et al; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904-14. doi:10.1016/j.ophtha.2014.04.024.
Kiddee W, Trope GE, Sheng L, Beltran-Agullo L, Smith M, Strungaru MH, et al. Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol. 2013;58:291-310. doi:10.1016/j.survophthal.2012.08.003.
Campochiaro PA, Hafiz G, Shah SM, Bloom S, Brown DM, et al; Famous Study Group. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology. 2010;117:1393-9.e3. doi:10.1016/j.ophtha.2009.11.024.
Takamura Y, Tomomatsu T, Matsumura T, Arimura S, Gozawa M, Takihara Y, et al. The effect of photocoagulation in ischemic areas to prevent recurrence of diabetic macular edema after intravitreal bevacizumab injection. Invest Ophthalmol Vis Sci. 2014;55:4741-6. doi:10.1167/iovs.14-14682.
Suñer JJ, Peden MC, Hammer ME, Grizzard WS, Traynom J, Cousins SW. RaScal.: A pilot study to assess the efficacy, durability, and safety of a single intervention with ranibizumab plus peripheral laser for diabetic macular edema associated with peripheral nonperfusion on ultrawide-field fluorescein angiography. Ophthalmologica. 2014; 26. doi:10.1159/000367902.
Mugit MM, Marcellino GR, Henson DB, Young LB, Patton N, Charles SJ, et al. Optos-guided pattern scan laser (Pascal)-targeted retinal photocoagulation in proliferative diabetic retinopathy. Acta Ophthalmol. 2013;91:251-8. doi:10.1111/j.1755-3768.2011.02307.x.
Patel RD, Messner LV, Teitelbaum B, Michel KA, Hariprasad SM. Characterization of ischemic index using ultra-widefield fluorescein angiography in patients with focal and diffuse recalcitrant diabetic macular edema. Am J Ophthalmol. 2013 ;155:1038-44.e2. doi:10.1016/j.ajo.2013.01.007.
Figueira J, Fletcher E, Massin P, Silva R, Bandello F, et al; EVICR.net Study Group. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study). Ophthalmology. 2018;125:691-700. doi: 10.1016/j.ophtha.2017.12.008.
Krill AE, Archer DB, Newell FW, Chishit ML Photocoagulation in diabetic retinopathy. Am J Ophthalmol. 1971;72:299-321. doi: 10.1016/0002-9394(71)91300-6.
Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology. 1992;99:753-9. doi: 10.1016/s0161-6420(92)31901-3.
Adelman R, Parnes A, Michalewska Z, Parolini B, Boscher C, Ducournau D. Strategy for the management of diabetic macular edema: the European vitreo-retinal society macular edema study. Biomed Res Int. 2015;2015:352487. doi: 10.1155/2015/352487.
Midena E, Frizziero L, Midena G, Pilotto E. Intraocular fluid biomarkers (liquid biopsy) in human diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2021;259:3549-60. doi: 10.1007/s00417-021-05285-y.
Pessoa B, Coelho J, Coelho C, Monteiro S, Abreu C, Figueira J, et al. Enzymatic vitreolysis for the treatment of fractional diabetic macular edema. Ther Adv Ophthalmol. 2019;11:2515841419869511. doi: 10.1177/2515841419869511.
Sadiq MA, Soliman MK, Sarwar S, Agarwal A, Hanout Met al; READ-3 Study Group. Effect of Vitreomacular Adhesion on Treatment Outcomes in the Ranibizumab for Edema of the Macula in Diabetes (READ-3) Study. Ophthalmology. 2016;123:324-9. doi: 10.1016/j.ophtha.2015.09.032.
Pessoa B, Coelho J, Malheiro L, Jose D, Pires S, Coelho C,et al. Comparison of ocular ultrasound versus SD-OCT for imaging of the posterior vitreous status in patients with DME. Ophthalmic Surg Lasers Imaging Retina. 2020;51:S50-3. doi: 10.3928/23258160-20200401-07.
Kulikov AN, Sosnovskii SV, Berezin RD, Maltsev DS, Oskanov DH, Gribanov NA. Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy: an optical coherence tomography study. Clin Ophthalmol. 2017;11:1995-2002. doi: 10.2147/OPTH.S146019.
Castillo Velazquez J, Aleman I, Rush SW, Rush RB. Bevacizumab before Diabetic Vitrectomy: A Clinical Trial Assessing 3 Dosing Amounts. Ophthalmol Retina. 2018;2:1010-20. doi: 10.1016/j.oret.2018.04.014.
Pessoa B, Dias DA, Baptista P, Coelho C, Beirao JN, Meireles A. Vitrectomy outcomes in eyes with fractional diabetic macular edema. Ophthalmic Res. 2019;61:94-9. doi: 10.1159/000489459.
Markan A, Agarwal A, Arora A, Bazgain K, Rana V, Gupta V. Novel imaging biomarkers in diabetic retinopathy and diabetic macular edema. Therap Adv Ophthalmol. 2020;12. doi:10.1177/2515841420950513
Vujosevic S, Torresin T, Bini S, Convento E, Pilotto E, Parrozzani R, Midena E. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular edema. Acta Ophthalmol. 2017;95:464-71. doi: 10.1111/aos.13294.
Vujosevic S, Simo R. Local and systemic inflammatory biomarkers of diabetic retinopathy: an integrative approach. Invest Ophthalmol Vis Sci. 2017;58:BIO68-75. doi: 10.1167/iovs.17-21769.
Cavalleri M, Cicinelli MV, Parravano M, Varano M, De Geronimo D, Sacconi R, et al. Prognostic role of optical coherence tomography after switch to dexamethasone in diabetic macular edema. Acta Diabetol. 2020;57:163-71. doi: 10.1007/s00592-019-01389-4.
Pessoa B, Ferreira A, Leite J, Figueira J, Meireles A, Beirao JM. Optical Coherence Tomography Biomarkers: Vitreous Status Influence in Outcomes for Diabetic Macular Edema Therapy with 0.19-mg Fluocinolone Acetonide Implant. Ophthalmic Res. 2021;64:639-47. doi: 10.1159/000515306.
Loganadane P, Delbosc B, Saleh M. Short-term progression of diabetic hard exudates monitored with high-resolution camera. Ophthalmic Res. 2019;61:3-9. doi: 10.1159/000493858.
Sander B, Thornit DN, Colmorn L, Strom C, Girach A, Hubbard LD, et al. Progression of diabetic macular edema: correlation with blood retinal barrier permeability, retinal thickness, and retinal vessel diameter. Invest Ophthalmol Vis Sci. 2007;48:3983-7. doi: 10.1167/iovs.06-1102.
Simo R, Stitt AW, Gardner TW. Neurodegeneration in diabetic retinopathy: does it really matter? Diabetologia. 2018;61:1902-12. doi: 10.1007/s00125-018-4692-1.
Zhang X, Wang N, Schachat AP, Bao S, Gillies MC. Glucocorticoids: structure, signaling and molecular mechanisms in the treatment of diabetic retinopathy and diabetic macular edema. Curr Mol Med. 2014;14:376-84. doi: 10.2174/1566524014666140128114414.
Ribbsam A, Parikh S, Fort PE. Role of Inflammation in Diabetic Retinopathy. Int J Mol Sci. 2018;19:942. doi: 10.3390/ijms19040942.
Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, et al.; DRCR Retina Network . Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA. 2019;321:1880-94. doi:10.1001/jama.2019.5790
Wykoff CC. Thresholds for Initiating Treatment of Eyes with Diabetic Macular Edema and Good Vision: Consideration of DRCR Net Protocol V Results. Ophthalmol Retina. 2019;3:917-9. doi: 10.1016/j.oret.2019.07.007.
Busch C, Okada M, Zur D, Fraser-Bell S, Rodriguez-Valdes PJ, et al; International Retina Group. Baseline predictors for visual acuity loss during observation in diabetic macular oedema with good baseline visual acuity. Acta Ophthalmol. 2020;98:e801-6. doi: 10.1111/aos.14390.
Baker CW, Almukhtar T, Bressler NM, Glassman AR, Grover S, Kim SJ, et al. Macular edema after cataract surgery in eyes without preoperative central-involved diabetic macular edema. JAMA Ophthalmol. 2013;131:870-9. doi: 10.1001/jamaophthalmol.2013.2313.
Chen XY, Song WJ, Cai HY, Zhao L. Macular edema after cataract surgery in diabetic eyes evaluated by optical coherence tomography. Int J Ophthalmol. 2016;9:81-5. doi: 10.18240/ijo.2016.01.14.
Bressler SB, Odia I, Maguire MG, Dhoot DS, Glassman AR, et al; Diabetic Retinopathy Clinical Research Network. Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial. JAMA Ophthalmol. 2019;137:382-9. doi: 10.1001/jamaophthalmol.2018.6786.
Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98:823-33.
Kousha O, Delle Fave MM, Cozzi M, Carini E, Pagliarini S. Diabetic maculopathy: multicolour and SD-OCT versus fundus photography. BMJ Open Ophthalmol. 2021; 6:e000514. doi: 10.1136/bmjophth-2020-000514.
Agemy SA, Scripsema NK, Shah CM, Chui T, Garcia PM, Lee JG, et al. Retinal Vascular Perfusion Density Mapping Using Optical Coherence Tomography Angiography in Normals and Diabetic Retinopathy Patients. Retina. 2015;35:2353-63. doi: 10.1097/IAE.0000000000000862
Cennamo G, Romano MR, Nicoletti G, Velotti N, de Crecchio G. Optical coherence tomography angiography versus fluorescein angiography in the diagnosis of ischaemic diabetic maculopathy. Acta Ophthalmol. 2017;95:e36-e42. doi: 10.1111/aos.13159.
Silva PS, Horton MB, Clary D, Lewis DG, Sun JK, Cavallerano JD, et al. Identification of Diabetic Retinopathy and Ungradable Image Rate with Ultrawide Field Imaging in a National Teleophthalmology Program. Ophthalmology. 2016;123:1360-7. doi: 10.1016/j.ophtha.2016.01.043.
Zhang M, Hwang TS, Dongye C, Wilson DJ, Huang D, Jia Y. Automated quantification of nonperfusion in three retinal plexuses using projection-resolved optical coherence tomography angiography in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2016;57:5101-6. doi: 10.1167/iovs.16-19776.
Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 1981;21:1-226.
Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, et al; Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677-82. doi: 10.1016/S0161-6420(03)00475-5.
Marques IP, Alves D, Santos T, Mendes L, Santos AR, Lobo C, et al. Multimodal Imaging of the Initial Stages of Diabetic Retinopathy: Different Disease Pathways in Different Patients. Diabetes. 2019;68:648-53. doi: 10.2337/db18-1077.
Silva PS, Cavallerano JD, Sun JK, Soliman AZ, Aiello LM, Aiello LP. Peripheral lesions identified by mydriatic ultrawide field imaging: distribution and potential impact on diabetic retinopathy severity. Ophthalmology. 2013;120:2587-95. doi: 10.1016/j.ophtha.2013.05.004.
Wessel MM, Aaker GD, Parlitsis G, Cho M, D’Amico DJ, Kiss S. Ultra-wide-field angiography improves the detection and classification of diabetic retinopathy. Retina. 2012;32:785-91. doi: 10.1097/IAE.0b013e3182278b64.
Dimitrova G, Chihara E, Takahashi H, Amano H, Okazaki K. Quantitative Retinal Optical Coherence Tomography Angiography in Patients With Diabetes Without Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2017;58:190-196. doi: 10.1167/iovs.16-20531.
Al-Sheikh M, Akil H, Pfau M, Sadda SR. Swept-Source OCT Angiography Imaging of the Foveal Avascular Zone and Macular Capillary Network Density in Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2016;57:3907-13. doi: 10.1167/iovs.16-19570.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Revista Sociedade Portuguesa de Oftalmologia
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Do not forget to download the Authorship responsibility statement/Authorization for Publication and Conflict of Interest.
The article can only be submitted with these two documents.
To obtain the Authorship responsibility statement/Authorization for Publication file, click here.
To obtain the Conflict of Interest file (ICMJE template), click here
